350 related articles for article (PubMed ID: 37174744)
1. The Role of Polo-Like Kinase 1 in Regulating the Forkhead Box Family Transcription Factors.
Moore XTR; Gheghiani L; Fu Z
Cells; 2023 May; 12(9):. PubMed ID: 37174744
[TBL] [Abstract][Full Text] [Related]
2. JNK-associated Leucine Zipper Protein Functions as a Docking Platform for Polo-like Kinase 1 and Regulation of the Associating Transcription Factor Forkhead Box Protein K1.
Ramkumar P; Lee CM; Moradian A; Sweredoski MJ; Hess S; Sharrocks AD; Haines DS; Reddy EP
J Biol Chem; 2015 Dec; 290(49):29617-28. PubMed ID: 26468278
[TBL] [Abstract][Full Text] [Related]
3. The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation.
Yuan C; Wang L; Zhou L; Fu Z
Cell Cycle; 2014; 13(5):807-19. PubMed ID: 24407358
[TBL] [Abstract][Full Text] [Related]
4. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression.
Fu Z; Malureanu L; Huang J; Wang W; Li H; van Deursen JM; Tindall DJ; Chen J
Nat Cell Biol; 2008 Sep; 10(9):1076-82. PubMed ID: 19160488
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 1-mediated phosphorylation of Forkhead box protein M1b antagonizes its SUMOylation and facilitates its mitotic function.
Zhang J; Yuan C; Wu J; Elsayed Z; Fu Z
J Biol Chem; 2015 Feb; 290(6):3708-19. PubMed ID: 25533473
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas.
Dibb M; Han N; Choudhury J; Hayes S; Valentine H; West C; Sharrocks AD; Ang YS
BMC Res Notes; 2015 Nov; 8():676. PubMed ID: 26576650
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer.
Gheghiani L; Shang S; Fu Z
Sci Rep; 2020 Jul; 10(1):12327. PubMed ID: 32704044
[TBL] [Abstract][Full Text] [Related]
8. Regulation of yeast forkhead transcription factors and FoxM1 by cyclin-dependent and polo-like kinases.
Murakami H; Aiba H; Nakanishi M; Murakami-Tonami Y
Cell Cycle; 2010 Aug; 9(16):3233-42. PubMed ID: 20716958
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX
BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy.
Studach L; Wang WH; Weber G; Tang J; Hullinger RL; Malbrue R; Liu X; Andrisani O
J Biol Chem; 2010 Sep; 285(39):30282-93. PubMed ID: 20624918
[TBL] [Abstract][Full Text] [Related]
11. Association of p21 with NF-YA suppresses the expression of Polo-like kinase 1 and prevents mitotic death in response to DNA damage.
Lin YC; Chen YN; Lin KF; Wang FF; Chou TY; Chen MY
Cell Death Dis; 2014 Jan; 5(1):e987. PubMed ID: 24407240
[TBL] [Abstract][Full Text] [Related]
12. The FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma.
Dibb M; Han N; Choudhury J; Hayes S; Valentine H; West C; Ang YS; Sharrocks AD
Br J Cancer; 2012 Nov; 107(10):1766-75. PubMed ID: 23037713
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1 (PLK1) signaling in cancer and beyond.
Iliaki S; Beyaert R; Afonina IS
Biochem Pharmacol; 2021 Nov; 193():114747. PubMed ID: 34454931
[TBL] [Abstract][Full Text] [Related]
14. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
15. Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications.
Shakeel I; Basheer N; Hasan GM; Afzal M; Hassan MI
J Drug Target; 2021 Feb; 29(2):168-184. PubMed ID: 32886539
[TBL] [Abstract][Full Text] [Related]
16. PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor.
Bucur O; Stancu AL; Muraru MS; Melet A; Petrescu SM; Khosravi-Far R
Discoveries (Craiova); 2014; 2(2):. PubMed ID: 26280018
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
Tsvetkov L; Stern DF
Cell Cycle; 2005 Jan; 4(1):166-71. PubMed ID: 15611664
[TBL] [Abstract][Full Text] [Related]
18. The substrates of Plk1, beyond the functions in mitosis.
Liu XS; Song B; Liu X
Protein Cell; 2010 Nov; 1(11):999-1010. PubMed ID: 21153517
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Polo-like kinase 1 by DNA damage in mitosis. Inhibition of mitotic PLK-1 by protein phosphatase 2A.
Jang YJ; Ji JH; Choi YC; Ryu CJ; Ko SY
J Biol Chem; 2007 Jan; 282(4):2473-82. PubMed ID: 17121863
[TBL] [Abstract][Full Text] [Related]
20. FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.
Pietilä M; Vijay GV; Soundararajan R; Yu X; Symmans WF; Sphyris N; Mani SA
Sci Rep; 2016 Apr; 6():23070. PubMed ID: 27064522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
